Alkermes (ALKS) Research & Development (2010 - 2026)

Alkermes (ALKS) has reported Research & Development for 17 consecutive years, with $154.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 27.39% year-over-year to $154.4 million in Q2 2026; TTM through Jun 2026 was $545.8 million, a 22.65% increase from a year earlier, with the FY2025 full-year figure at $480.0 million, up 7.57% from the prior year.
• Research & Development was $154.4 million for Q2 2026 at Alkermes, down from $155.6 million in the prior quarter.
• Over five years, Research & Development peaked at $293.3 million in Q4 2023 and troughed at $63.8 million in Q1 2023.
• A 5-year average of $117.7 million and a median of $109.3 million in 2022 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 697.6% in 2022 and plunged 66.28% in 2024, its largest moves.
• Over 5 years, Research & Development stood at $103.0 million in 2022, then jumped by 184.86% to $293.3 million in 2023, then sank by 66.28% to $98.9 million in 2024, then advanced by 21.62% to $120.3 million in 2025, then advanced by 28.35% to $154.4 million in 2026.
• The last three Research & Development figures came in at $154.4 million (Q2 2026), $155.6 million (Q1 2026), and $120.3 million (Q4 2025), per Business Quant data.